PT  - JOURNAL ARTICLE
AU  - Fouda, Menna
AU  - George, Angela
AU  - Banerjee, Susana
TI  - #735 Clinical outcomes in primary mucinous ovarian carcinoma: a single UK centre experience
AID  - 10.1136/ijgc-2023-ESGO.637
DP  - 2023 Sep 01
TA  - International Journal of Gynecologic Cancer
PG  - A305--A305
VI  - 33
IP  - Suppl 3
4099  - http://ijgc.bmj.com/content/33/Suppl_3/A305.2.short
4100  - http://ijgc.bmj.com/content/33/Suppl_3/A305.2.full
SO  - Int J Gynecol Cancer2023 Sep 01; 33
AB  - Introduction/Background Mucinous ovarian carcinoma (MOC) is a rare subtype of epithelial ovarian carcinoma (<5%). MOC is most frequently diagnosed at early stage & is associated with a good prognosis while advanced-stage & relapsed disease effective treatment options limited & outcomes are worse. Given the paucity of prospective trials in MOC, we performed a retrospective evaluation of treatment & outcome including management in recent years, to help guide discussions with patients (pts) in practice & clinical trial development.Methodology A retrospective analysis of patients with MOC patients treated at Royal Marsden hospital between December (2014 – 2021) was conducted using the Cancer Database. The clinicopathological features & survival outcomes were evaluated using Kaplan-Meier analyses.Results 27 patients were identified. Median age was 44. The FIGO stage distribution at diagnosis was: I 20 (74.1%), II 3 (11.1%); III 3 (11.1%) and IV 1 (3.7%). 15 pts (57.7%) had raised CA19.9 while 13 (48.1%) had raised CA125 at diagnosis. 14 pts (51.9%) received adjuvant chemotherapy. The chemotherapy regimens received were Carboplatin in (2) pts, Carboplatin/paclitaxel (10) pts, CapOx (1) & FOLFOX (1) pt.7 pts(25.9%) developed disease relapse (5 (21.7%) & 2 pts (50%) had Stage I/II and III/IV disease at diagnosis, respectively. 2 pts (7.4%) were treated within clinical trials in relapsed settings.(4) pts were treated with Bevacizumab (14.8%), 2 pts had immunotherapy (7.4%) & 1 pt had Her2 targeted therapy. The Median overall survival was 91.3 & 62.9 months for stage I/II and III/IV respectively.Carboplatin/taxane, CapOx, were used in the first relapse settings & subsequent treatment options included carboplatin/paclitaxel, carboplatin/Gemcitabine, liposomal doxorubicin & weekly paclitaxel.Abstract #735 Figure 1 Conclusion New treatment options are urgently needed to improve the clinical outcomes of women with advanced and recurrent mucinous ovarian carcinoma.Disclosures No Disclosures